Grace Therapeutics, Inc. (GRCE) › Cash & EquivalentsGrace Therapeutics, Inc. (GRCE) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2018: $6.42M2019: $16.87M2020: $14.24M2021: $50.94M2022: $30.34M2023: $27.88M2024: $23.00M2025: $22.13M$22.13M2018Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$22.13M-3.8%2024$23.00M-17.5%2023$27.88M-8.1%2022$30.34M-40.4%2021$50.94M+257.7%2020$14.24M-15.6%2019$16.87M+162.7%2018$6.42M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share